John G.F. Cleland

TL;DR: Levosimendan, a novel calcium sensitiser, improves cardiac performance and symptoms without increasing oxygen consumption, and decreases the mortality of patients with low‐output heart failure.

TL;DR: There has been growing interest in using phosphodiesterase‐5 (PDE‐5) inhibitors in HF associated with group 2 pulmonary hypertension (PH), with benefits reported on pulmonary haemodynamic and functional status in single‐centre trials.

TL;DR: This global, prospective, and observational study is designed to characterize patient trajectories longitudinally during and following an index hospitalization for HF.

TL;DR: This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the American College of Cardiology meeting in March 2007.

TL;DR: It is clear that implantable defibrillators should be considered for patients with heart failure who have been resuscitated from ventricular fibrillation or sustained ventricular tachycardia, and cardiac resynchronization is a promising new therapy that may relieve the symptoms of heart failure in appropriately selected patients resistant to optimal pharmacologic therapy.